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journal homepage: www.elsevier.com/locate/ihjAluminum phosphide (ALP) is used commercially as an
agricultural rodenticide/insecticide under various names in
Indian subcontinent. Unfortunately, it has become a drug of
choice among young adults for the purposes of suicide,
especially in northern India, with very high mortality rates.1
When consumed orally it rapidly interacts with water and
hydrochloric acid in the stomach to release phosphene gas,
which is absorbed in the blood within 10–15 min. Therefore, if
the victim her/himself does not vomit out the pills, the oral
therapies administered in the emergency rooms to remove the
toxic agent from the gastrointestinal tract are ineffective in
majority of the cases. The dissolved phosphene gas in the
circulation is distributed rapidly throughout the body and
interacts at the cellular level with the mitochondria to inhibit
oxidative phosphorylation in the multiple organs, especially
the heart, lung, liver, and kidneys, within an hour.2 Therefore,
by the time the victims arrive at the hospital (which in the
present series was 7–8 h), the toxic effects on the organ
systems are well established. Even if such patients are brought
within an hour of ingestion of ALP pills, necessary antidote
may not be available to neutralize the phosphene gas in the
body, and all medical measures are aimed at supportive care in
almost all cases, until the toxin is cleared via lungs and
kidneys. If the patient survives, the cellular function returns to
normal over the following ﬁve to seven days.3
The major factor in mortality from acute ALP poisoning is
the progressive development of severe left ventricular (LV)
dysfunction, circulatory collapse, respiratory gas exchange
impairment with development of systemic hypotension and
metabolic acidosis.4 The reported variations in the mortality in
various case reports may depend upon the level of cardiovas-
cular and respiratory impairment in individual cases. In
patients with milder degree of shock, supportive measures
including ﬂuids, ionotropic support, and intra-aortic balloon
pump may help the patient survive until the phosphene toxin
is cleared. However according to the available data, the
mortality approaches 100% in patients with severe shock.4
As the LV dysfunction and respiratory impairment in patients
with ALP poisoning are potentially reversible within 5–7 days,it may be useful to use extracorporeal life support system
(ECLS) such as veno-arterial extracorporeal membrane oxy-
genation (VA ECMO) that can support both cardiovascular and
lung functions temporarily in patients with severe shock, to
potentially improve survival. How do we deﬁne ‘‘severe
shock’’. In the SHOCK trial, the cardiogenic shock was deﬁned
clinically as systolic blood pressure (SBP) of <90 mm of Hg for
more than 30 min or use of inotropic support to maintain SBP
>90 mm of Hg with evidence of systemic hypoperfusion
(mental status change, decreased urine output, etc.).5 The
authors deﬁned ‘‘severe shock’’ based on the criteria of severe
LV dysfunction (EF < 35%) associated with BP <80 mm of Hg in
spite of ionotropic support, presence of severe metabolic
acidosis (pH < 7.0), or both. The mortality rate of 87% with
current conventional supportive care in their series does
afﬁrm the deﬁnition of ‘‘severe shock’’ and supports the
indication for use of ECMO in this group of patients.
Extracorporeal Life Support Organization (ELSO) guidelines
suggest that ECLS should be considered, when the risk of
mortality is 50% or greater, and is indicated, when the risk of
mortality is 80% or greater.6 The survival rate of 67% in the
patients with acute ALP poisoning (AALPP) treated with VA
ECMO in the present series compares well with the data from
ECLS registry report, in which the adults receiving ECMO for
various respiratory, cardiac, and extracorporeal cardiopulmo-
nary resuscitation indications had the survival rates to
discharge or transfer of 58%, 40%, and 30% respectively.6
The data for the use of ECMO in poisoning cases are limited.
Recently Masson and colleagues published a retrospective
cohort analysis of the role of ECMO in 14 out of 62 patients with
cardiac arrest or severe shock due to poisoning from various
cardio-toxic drugs at two French hospitals over a 10-year
period.7,8 The survival was signiﬁcantly better in the patients
receiving ECMO compared to conventional supportive therapy
(86% vs 48%). ECLS support remained associated with lower
mortality in multivariate analysis with an odds ratio of 0.18
(95% conﬁdence interval 0.03–0.96, p = 0.04). Although this
analysis does not include any patient with ALP poisoning, it
nevertheless seems to support the use of ECMO in cases of
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patients with cardiotoxic drug poisoning.
The pathophysiology of shock in patients with ALP poisoning
may be multifactorial and different compared to other poisons,
but the current observational cohort series do suggest that
short-term mortality can be reduced signiﬁcantly with ECMO in
addition to conventional supportive measures. Even though
mortality is improved with the use of ECMO in AALPP, it still
remains high due to various factors such as the dose of the drug
ingested, the time to presentation, time to initiation of care
including ECMO, as well as the complications related to the
device. The major complication related to ECMO is bleeding.6,9A
recent meta-analysis by Cheng et al., analyzed the use of ECMO
in a group of 1866 patients from 20 studies between 2000 and
2012, and discovered that ECMO utilized for cardiogenic shock or
cardiac arrest was associated with major or signiﬁcant bleeding
rate of 41%.9 Acute renal insufﬁciency was present in 56% of
patients with 46% requiring renal replacement therapy. It is
difﬁcult to know, whether progression of renal failure is part of
the initial insult or worsening due to the device. The arterial
ischemic complications' rates due to the large size of the
cannula are also high (lower extremity ischemia, 17%; fasciot-
omy or compartment syndrome, 10%; lower extremity amputa-
tion, 4.7%). However, the rates of these complications can be
reduced with placement of distal perfusion sheath in the
superﬁcial femoral artery.10 Therefore, it is important that
the use of ECMO for ALP poisoning with cardiogenic shock be
restricted at centers with expertise in the use and management
of extracorporeal life support systems. It is also important to
consider the ﬁnancial impact of ECMO on patients and their
families, so its use can be avoided in patients already presenting
late with severe multi-organ failure or after prolonged CPR with
very low chance of survival. But it is also important to recognize
that in India, the majority of these cases are young adults with
no other signiﬁcant comorbidities, who will have signiﬁcant
lifetime quality-adjusted life years gain.
In conclusion, the current cohort series published show
that at tertiary care center in India, use of ECMO in patients
with acute ALP poisoning with severe shock saves young lives,
but the challenge is to ﬁrst deﬁne the true incidence. The
majority of the cases of AALPP are from rural areas and the
incidence of poisoning and shock may be much larger than
seen at tertiary care centers. Therefore, the question arises,
whether it is feasible and practical to rapidly transfer all
patients with suspected ALP poisoning and hypotension
before the onset of shock and multi-organ failure to centers
with availability of ECMO. Answer may be more afﬁrmative. As
the technology for percutaneous ECMO support like Cardio-
Help becomes more widely available, one can potentially also
consider it prior to establishment of severe acidosis. However,
the currently available data strongly suggest the use of VA
ECMO in patients with AALPP with ‘‘severe shock’’.
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